Dear valued Pharmulous patient,

We are aware of the recent changes to the GPhC guidelines surrounding the online prescribing of high risk medications which include the popular weight loss medications Mounjaro and Wegovy.

We are empathetic to the expected heightened anxiety our patients are experiencing secondary to these changes. Please be reassured that both existing and new Pharmulous patients should expect to receive the same high standard of care and support they have always experienced using our services ensuring patient safety is just as a priority to us as it is to the GPhC.

We will continue to ensure the safe and appropriate access to such medications is not hindered or jeopardised in any way and we stand firm in our stance with supporting our patients on both their weight loss and maintenance journeys with no abrupt cut off.

Of course, with the tightening of these regulations we will look at how the logistics of our prescribing can further align with that of the GPhC’s recommendations. This will be explored thoroughly and where deemed appropriate a gradual adoption of the most convenient methods of consulting and prescribing to ensure a seamless transition.

We promise to continue to be honest and open in sharing any changes that may result from the above whilst ensuring we keep our competitive pricing down and fast despatch as well as support to the best of our capabilities.

We appreciate your support and patience during this period and as always if there are any questions or concerns please do not hesitate to contact us via our customer service email [email protected]